Q4 GAAP revenues of $562.2 million, up 4.9% from Q4 2023. Organic Q4 ASV plus professional services of $2,272.8 million, up 4.8% year over year. Q4 GAAP operating margin of 22.7%, up approximately 110 bps year over year, and adjusted operating margin of 35.8%, up 240 bps from the prior year. Q4 GAAP diluted EPS […]

MONTREAL, Sept. 19, 2024 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, is pleased to congratulate its client EarthGrid, which announced yesterday

-Achilles to discontinue development of TIL-based cNeT therapy- -Cash position of $95.1 million as of June 30, 2024- -BofA Securities engaged to provide strategic financial advice- LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL) today announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Slam Corp. (OTCQX: SLAMF), a special purpose acquisition company led by World Series Champion Alex Rodriguez, has qualified to trade on the OTCQX(R) Best Market. Slam Corp. previously

BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s nomlabofusp Phase 1 studies and Phase 2 dose exploration study, some of which has been previously disclosed, will be presented at

TORONTO, Sept. 19, 2024 (GLOBE NEWSWIRE) — Guardian Capital LP (the “Manager“), the manager of Guardian i3 US Quality Growth ETF (the “Fund“), today announced that it has changed the name of the Fund effective immediately to Guardian i3 US Quality Growth Fund (the “Name Change“). There are no changes to the investment objective, strategies

LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced the appointment of Matthias Will, M.D., as Chief Development Officer. Dr. Will is joining Autolus’ executive team and will lead the company’s development organization effective September 30, 2024. “Matthias has a proven

NAPLES, Fla., Sept. 19, 2024 (GLOBE NEWSWIRE) — Beasley Broadcast Group Inc. (Nasdaq: BBGI), a multi-platform media company (the “Company”), today announced that its Board of Directors (the “Board”) has approved a reverse stock split of its Class A Common Stock and Class B Common Stock (collectively, the “Common Stock”) at a ratio of 1-for-20.

Press Release Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor Geneva, Switzerland – September 19, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental disorders, announced today that Dr. Paulo Fontoura will be joining their drug development team as Chief

The Importance of 3D-Circuits in Healthcare Doctors and clinicians need the best tools. Hospitals need the best supply contracts and equipment. Everyone benefits from new cutting-edge engineering in medical devices and clinical hardware. In the race to fine-tune healthcare systems and deliver the best patient care, technology plays an enormous role. We’ve found that these